| |
Article Title |
Author(s) |
Pages |
|
|
|
Editorial Board
|
|
CO2
|
|
| Editorials |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Editorial
09 September 2011
“See you again in four years in Nonnweiler…”
|
On behalf of the editors:,
Rainer Scheer
|
S1
|
|
|
|
Editorial
09 September 2011
“Bis in 4 Jahren in Nonnweiler…”
|
Rainer Scheer
|
S2
|
|
| Lectures of invited speakers |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Lectins – Potential sources and potential benefits
Introduction: The term lectin was introduced by William Boyd in 1954 and used to characterize proteins with an ability to bind carbohydrates. Lectins can be classified on the basis of their carbohydra...
|
Wolfgang Kreis
|
S3
|
|
|
|
Mistletoe lectins as biologically active substances in aqueous mistletoe extracts
Aqueous mistletoe extracts contain a large variety of potentially therapeutically active substances, which are altogether responsible for the wide range of physiological effects seen after mistletoe a...
|
U. Pfüller,
U. Schumacher
|
S3-S4
|
|
|
|
The role of inflammation in the pathogenesis of cancer
Chronic inflammation plays a critical role in tumorigenesis. Thus, the persistence of several toxic influences (i.e. cigarette smoking, exposure to asbestos and silica, etc.), viral (i.e. Hepatitis B ...
|
Reinhild Klein
|
S4
|
|
|
|
Molecular approaches for individualized tumor therapy with standard drugs, phytochemicals, and medicinal herbs
Assays to predict the response of tumors towards chemotherapy are relevant for custum-tailored, individualized therapies. Clinically, chemotherapy is frequently followed by drug resistance (). Since m...
|
Thomas Efferth
|
S4
|
|
|
|
State of the art and new developments of anthroposophic mistletoe therapy – Results from a series of expert conferences hosted by the German anthroposophic doctor's association (GAAeD) 2008–2011
During a 4 years period (begin of 2008–end of 2011) the German anthroposophic doctor's association (GAAeD) hosted a series of 8 expert conferences, attended each by 100–130 experienced physicians and ...
|
Thomas Breitkreuz
|
S5
|
|
|
|
Clinical research on mistletoe therapy in cancer – Status quo, current projects and developments
A large number of clinical studies has been conducted to investigate the influence of mistletoe therapy on cancer, especially with regard of quality of life, survival, tumour response and safety issue...
|
Gunver S. Kienle
|
S5
|
|
|
|
Revision of the summary of product characteristic of anthroposophic preparations in parenteral dosage forms containing mistletoe – Result of a compromise between the marketing authorization holders and the German Federal Institute for Drugs and Medical Devices
Purpose: Due to multiple court cases regarding the labelling of anthroposophic preparations in parenteral dosage forms containing mistletoe the Federal Institute For Drugs and Medical Devices (BfArM) ...
|
C. Werner,
M. Kirch,
I. Spingler-Kliemsch,
W. Knöss
|
S5
|
|
|
|
Options and limitations of ductal pancreatic cancer treatment
Ductal pancreatic cancer has still a dismal prognosis. Late diagnosis due to missing or unspecific early symptoms, early metastases and a relative resistance to radio- and chemotherapy characterize th...
|
Thomas Seufferlein
|
S5-S6
|
|
|
|
Mistletoe therapy in adjuvant and palliative therapy of pancreatic carcinoma: Concepts–facts–perspectives
Introduction: Pancreatic adenocarcinoma (PCa) is still a diagnostic and therapeutic challenge. Less than 10% of PCa are curable with R0-resection at time of diagnosis, 5-year survival rate is<1%, m...
|
H. Matthes,
D. Buchwald,
F. Schad
|
S6
|
|
| Short lectures |
| Biology, pharmacy, immunology, in vitro-tests |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Localization of mistletoe lectins ML I-III in Viscum album L. by immunofluorescent and immunogold labeling
Purpose: Because of their immunomodulatory and cytotoxic effects mistletoe extracts play an important role as phytotherapeutic adjuvants in cancer therapy. Mistletoe lectins ML I-III contribute essent...
|
W. Blaschek,
J.-C. Gramann,
B. Classen
|
S7
|
|
|
|
Organ specific and seasonal accumulation of viscotoxin-isoforms in Viscum album ssp. album
Purpose: Botanical aspects of presence and dynamics of the pharmacologically active substances in Viscum album not only allow characterising mistletoe but also represent fundamentals of pharmaceutical...
|
K. Urech,
G. Schaller,
H. Ramm,
S. Baumgartner
|
S7
|
|
|
|
Genuine bilayer formation during glancing impact of drops on liquid surfaces both covered by lipid monolayers
Purpose: A variety of flow processes is used during the manufacturing of mistletoe preparations. The intriguing question is whether permanent colloidal structures can be formed during these processes ...
|
M. Vranceanu,
G. Leneweit
|
S7-S8
|
|
|
|
Therapeutic efficacy of natural compounds from Viscum album L. in acute lymphoblastic leukaemia
Viscum album L. (mistletoe) is one of the most widely used complementary treatment in cancer therapy. However, due to their poor solubility, triterpenes, which are known to possess anti-cancer propert...
|
Catharina I. Delebinski,
Sebastian Jäger,
Kristin Kemnitz-Hassanin,
Günter Henze,
Holger N. Lode,
Georg Seifert
et al.
|
S8
|
|
|
|
Amplification of anti-melanoma activity of mistletoe extracts by enrichment with solubilized triterpene acids
Mistletoe extracts are often used in complementary cancer therapy although the efficacy of that therapy is controversially discussed. Approved mistletoe extracts contain mainly water soluble compounds...
|
C.M. Strüh,
S. Jäger,
A. Kersten,
C.M. Schempp,
A. Scheffler,
S.F. Martin
et al.
|
S8
|
|
|
|
Viscum album inhibits cell growth, migration and invasion of pediatric tumor cell lines – But effects are limited at concentrations found in serum
Purpose: Viscum album (mistletoe) is a common complementary therapy used by cancer patients in Germany. Its safety is currently being explored in a German multicenter clinical trial in pediatric oncol...
|
T.J. Zuzak,
M. Bornschein,
K. Menke,
H. Stephan,
K. Pajtler,
J. Eisenbraun,
A. Schramm
et al.
|
S8-S9
|
|
| Clinical practice and clinical research |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Two cases of durable regression of primary B-cell cutaneous lymphoma following mistletoe treatment alone
Introduction: Viscum album L. extracts (VAEs) are widely used in integrative cancer treatment, usually with subcutaneous administration of low doses of VAEs – and this approach has been shown to impro...
|
M. Orange,
A. Lace,
M. Fonseca,
H.B. von Laue,
S. Geider
et al.
|
S10
|
|
|
|
Observational study on treatment of lymphocytic Non Hodgkin's Lymphoma (CLL) with Viscum album products Helixor P or A: Clinical course and safety
Background: CLL is a malignant disorder of B lymphocytes. Patients’ lifetime is mostly limited by uncontrollable terminal infections. The aim of the presentation is to determine effects and safety of ...
|
J. Gutsch,
S. Rieger,
D. Schlodder
|
S10
|
|
|
|
Different routes of application in mistletoe therapy – Effect on bone marrow and blood profile. Clinical significance
Background: For cancer patients, the absolute lymphocyte count in peripheral blood has well-substantiated prognostic potential for recurrence free survival and survival following chemotherapy. A low a...
|
Jürgen Johannes Kuehn
|
S11
|
|
|
|
High dose intravenous mistletoe treatment – Clinical results, laboratory findings and adverse events in a series of 17 patients with 107 intravenous applications
Context: Based on 10 years experience with subcutaneous, intratumoral and intrapleural mistletoe treatment, high dose intravenous mistletoe treatment for advanced metastasised malignant disease was st...
|
K.R. Wiebelitz,
A.-M. Beer
|
S11
|
|
|
|
Safety of higher dosages of Viscum album L. in animals and humans – Systematic review of immune changes and safety parameters
Viscum album L extracts (VAE, mistletoe) and isolated mistletoe lectins (ML) have immunostimulating properties and a strong dose-dependent cytotoxic activity. To answer the question whether VAE or ML ...
|
Gunver S. Kienle,
Renate Grugel,
Helmut Kiene
|
S11-S12
|
|
|
|
NCCAM/NCI phase 1 study of mistletoe extract and Gemcitabine in patients with advanced solid tumors
Background: European mistletoe extracts are used for cancer treatment in Europe. Controlled studies of safety and toxicity in cancer treatment based on dosing have not been published. This novel phase...
|
P.J. Mansky,
D.B. Wallerstedt,
T. Sannes,
J. Stagl,
L.L. Johnson,
M.R. Blackman,
J.L. Grem,
S.M. Swain,
D. Schlodder,
B.P. Monahan
et al.
|
S12
|
|
|
|
Supportive therapy with mistletoe extract in tumor patients – Results of four controlled pharmacoepidemiological cohort studies as basis for prospective studies
Aim of the studies: Efficacy and tolerance of mistletoe extracts Iscador® (ISC) P, Qu, and M (host trees pinus pine, quercus oak, malus apple tree) as a supportive therapy in patients with primary mal...
|
M. Werner,
P.R. Bock,
J. Hanisch,
G. Stauder
|
S12-S13
|
|
|
|
Clinical outcome study in pancreatic carcinoma using Viscum album therapy in an integrative approach
Viscum therapy is one of the mainstays of integrative cancer treatment in Germany and is also widely used in pancreatic cancer. Conventional treatment modalities in this type of cancer (12000 new case...
|
G. Spahn,
V. Schindler,
C. Heyder,
H. Rieß,
A. Gerhards,
H.B. von Laue,
M. Woernle,
M. Nabrotzki,
G. Leneweit,
A. Merkle,
F. Schad
et al.
|
S13
|
|
|
|
Multimodal Viscum album L. treatment in an integrative oncological setting in patients with advanced pancreatic carcinoma
Background: Integrative therapy concepts are of growing interest in oncology. Viscum album L. (VAL) has become a widely used concurrent option in cancer treatment. Patients with advanced pancreatic ca...
|
F. Schad,
D. Buchwald,
A. Merkle,
S. Popp,
M. Kröz,
H. Matthes
et al.
|
S13
|
|
|
|
A randomized placebo controlled study on Viscum album (Iscador P) treatment of Equine Sarcoids in horses
Purpose: The purpose of this trial was to evaluate the effects of a 105 days single treatment protocol applying subcutaneously Iscador P series therapy in comparison to placebo control in horses with ...
|
O. Christen-Clottu,
V. Gerber,
D. Burger,
P. Klocke
|
S13-S14
|
|
|
|
Viscum album fermentatum Pini versus oral Etoposide as adjuvant treatment in osteosarcoma patients after second relapse
Background: Osteosarcoma is a highly malignant bone tumor affecting mainly adolescents. With the recommended neoadjuvant chemotherapy it can be cured in approximately 60% of cases. Few experimental dr...
|
A. Longhi,
E. Mariani,
J. Kuehn,
M. Reif
|
S14
|
|
|
|
Randomised, open phase II study of tolerance, safety and efficacy of Viscum album extract in the palliative, additive treatment of advanced non-small cell lung carcinoma (NSCLC)
Introduction: Mistletoe therapy (Viscum album L. extracts, VAE) for NSCLC has been documented in case histories and 7 clinical studies, 5 of which are randomised controlled studies.
|
Christian Grah,
Burkhard Matthes,
Helmut Happel
|
S14-S15
|
|
|
|
Dose-escalation-study with a mistletoe extract from the ash tree as intravesical instillation in patients with superficial bladder cancer: An ICH/GCP phase Ib/IIa study
Purpose: The aim of this phase Ib/IIa study was to investigate the maximum tolerable concentration of Abnobaviscum® Fraxini 20mg for intravesical instillation in patients with superficial bladder canc...
|
Jürgen Eisenbraun
|
S15
|
|
|
|
Quality of life during mistletoe therapy of cancer patients – An exploratory study with the additional use of questionnaires
Purpose: Several questionnaire-based clinical studies have shown that mistletoe therapy (MT) as part of a multi-modal therapeutic approach may improve patients’ quality-of-life (QoL). The purpose of t...
|
M. Brandenberger,
A.P. Simões-Wüst,
M. Rostock,
L. Rist,
R. Saller
et al.
|
S15
|
|
|
|
Retrolective studies on the survival of cancer patients treated with mistletoe extracts – A meta analysis
Background: Studies reveal that cancer patients are actively seeking treatments and coping strategies which might be helpful to extend survival time. In this respect retrolective studies have been app...
|
T. Ostermann,
A. Büssing
|
S16
|
|
|
|
Mistletoe and chemotherapy responsiveness of different scales in oncological patients undergoing chemotherapy
Introduction: In current patient-related outcomes (PRO) in oncology there is a difference between scales recording the effects of radio-/chemotherapy alongside functional and role scales (e.g. EORTC Q...
|
M. Kröz,
M. Reif,
R. Zerm,
F. Schad,
H.B. von Laue,
T. Storch,
B. Brinkhaus,
G. Feder,
S.N. Willich,
M. Girke
et al.
|
S16
|
|
|
|
An online documentation for specific courses of therapy in oncology: Www.bestcase-oncology.com
Purpose: Unusual long-term courses or long-term survival of patients with advanced tumors are known by all medical oncologists. Yet there is no systematic collection and analysis of case reports in wh...
|
Boris Müller-Hübenthal
|
S16-S17
|
|
|
|
Mistletoe therapy in anthroposophical hospitals in Switzerland
Background: Cancer therapy with mistletoe (Viscum album L.) is used in Switzerland with good results since decades in anthroposophical hospitals. However, systematic and comprehensive documentation to...
|
R. Ziegler,
M. Reif,
B. Böhringer,
R. Mikolasch,
A.P. Simões-Wüst,
M. Kilcher,
M. Schenker,
A. Merkle,
F. Schad
et al.
|
S17
|
|
| Poster presentations |
| Biology, pharmacy, immunology, in vitro-tests |
| |
Article Title |
Author(s) |
Pages |
|
|
|
The potential of a mistletoe (Viscum album L.) extract to alleviate adverse effects of cancer chemotherapy: An in vitro study
Objectives: Mistletoe extracts have been shown to provide deoxyribonucleic acid (DNA)-stabilizing effects in human peripheral blood mononuclear cells (PBMC) in vitro. We investigated the effect of a m...
|
J. Burkhart,
C. Wälchli,
P. Heusser,
U. Weissenstein,
A.-C. Andres,
S. Baumgartner
et al.
|
S18
|
|
|
|
Aqueous mistletoe extracts versus purified mistletoe lectin-I (pML-I): Effects on melanoma growth and spread in a human melanoma xenograft scid mouse model
Purpose: The aim of this study is to investigate the effects of purified mistletoe lectin-I (pML-I) in comparison to those of the equivalent ML-I dose contained in the aqueous mistletoe extract Iscado...
|
A. Dahl,
A. Meyer,
P. Dautel,
U. Pfüller,
F. Sander,
A. Ehm,
U. Schumacher
et al.
|
S18
|
|
|
|
Effects of Viscum album L. extracts in neuroblastoma in vitro and in vivo
Viscum album L. (mistletoe) is one of the most widely used complementary treatment in cancer therapy. Differential effects of defined lectin- and triterpene-containing mistletoe extracts on neuroblast...
|
Catharina I. Delebinski,
Sebastian Jäger,
Kristin Kemnitz-Hassanin,
Günter Henze,
Holger N. Lode,
Georg Seifert
et al.
|
S19
|
|
|
|
Assessment of extracts from mistletoe (Viscum album) for herb–drug interaction by inhibition and induction of cytochrome P450 activities
Purpose: The aim of this in-vitro study was the assessment of three commercially available extracts from mistletoe (Viscum album L.) grown on ash tree (Abnobaviscum® Fraxini 20mg), on fir (Abnobaviscu...
|
J. Doehmer,
J. Eisenbraun
|
S19
|
|
|
|
Selective quantification of mistletoe lectin I in pressed mistletoe juice after inhibition of mistletoe lectin II and III
Purpose: Mistletoe extracts are usually standardized with regard to their mistletoe lectin I (ML I) content. In general, the applied enzyme-linked lectin assays (ELLA) using asialofetuin as substrate ...
|
W.F. Eisenbeiß,
F. Vogiatzi,
W. Kreis
|
S19-S20
|
|
|
|
Cyclodextrin solubilised triterpene extracts show anti-tumorigenic effects on B16.F10 melanoma cells in vitro
There are numerous reports about anti-tumorigenic effects of triterpene extracts (TE) from plants and single triterpenoids like oleanolic acid (OA) or betulinic acid (BA) on cancer cell lines in vitro...
|
S. Jäger,
C.M. Strüh,
C.M. Schempp,
A. Scheffler,
S.F. Martin
et al.
|
S20
|
|
|
|
Interactions between proteins of mistletoe or human serum and lipid membranes
Background: During cancer therapy involving mistletoe, unspecific lipid/protein interactions may occur between proteins of mistletoe and human cell membranes as well as between serum proteins and coll...
|
Y. Klapper,
M. Vranceanu,
R. Popa,
G. Leneweit
|
S20
|
|
|
|
Comparative investigation of monosaccharides and sugar alcohols in mistletoes (Viscum album L.) from different host trees
Purpose: The chemical composition and biological activities of mistletoe extracts depend on various factors, among which the host tree species is of considerable importance. Therefore, the purpose of ...
|
Mira Kohl,
Christian Bäcker,
Martina Wurster,
Ulrike Lindequist,
Ulrich Meyer,
Florian Stintzing
et al.
|
S20-S21
|
|
|
|
Lectins are the pharmacologically active constituents in the standardized mistletoe extract PS76A2 (Lektinol®)
Purpose: Aqueous extracts from Viscum album L. used in adjuvant cancer therapy, dependent on the way of manufacturing, may contain a mixture of different constituents. The most important compounds are...
|
U. Mengs,
U. Pfüller,
W. Blaschek
|
S21
|
|
|
|
Selective inactivation of the B-subunit of mistletoe lectins and other RIP-II-lectins in ionic liquids
Mistletoe lectins (ML-I, II, III) are prominent members of the class II ribosomal inactivating proteins (RIP) consisting of a toxic A-chain and a sugar binding B-chain. Further members of the class II...
|
U. Pfüller,
K. Pfüller
|
S21
|
|
|
|
Viscotoxin 1-PS from Scots pine mistletoe– Ecophysiological Hints
Purpose: Due to an antioxidant substrate, high proportions of reducible disulfide bridges are typically for the viscotoxin 1-PS from Scots Pine (Pinus silvestris L.) mistletoe (Viscum album ssp. austr...
|
Stefan Seegmüller
|
S22
|
|
|
|
Sensitivity of primary cultures of breast cancer cells to different Iscador®-preparations
Purpose: The purpose of this study was to find out which Iscador®-preparation induces the strongest cytotoxic effect in the different subtypes of breast cancer tumours. With this information it should...
|
A.P. Simões-Wüst,
L. von Balthazar,
M. Werner,
L. Rist,
A. Kuck,
J. Rohrer
et al.
|
S22
|
|
|
|
Effect of Viscum album lipohilic extract on human immunocompetent cells in vitro
Purpose: Viscum album lipohilic extract (VALE) contains triterpenes known to possess biological functions such as antioxidative, anti-inflammatory, immunomodulatory, wound-healing and anticancer activ...
|
U. Weissenstein,
U. Toffol-Schmidt,
S. Baumgartner,
K. Urech
|
S22-S23
|
|
| Clinical practice and clinical research |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Orally administered Viscum album Quercus dilutions in the therapy of feline fibrosarcoma in cats
Purpose: The purpose of this prospective observational study was to evaluate the prophylactic effects of an orally administered Viscum album Quercus preparation (Hiscia, CH-Arlesheim) in cats after su...
|
U. Biegel,
Katja Ruess-Melzer,
P. Klocke
|
S24
|
|
|
|
Does a treatment with Viscum album (Iscador® P) in patients with breast cancer influence the expression of the T-cell receptor (TCR)-zeta chains of T- and NK-cells?
Purpose: One purpose of this feasibility study was the identification of new surrogate parameters for the investigation of the influence of Viscum album (Iscador® P, IP) on immune functions in patient...
|
C.v. Hagens,
T. Giese,
A. Staudt,
A. Glenz,
B. Reinhard-Hennch,
A. Loewe-Mesch,
J.J. Kuehn,
U. Abel,
J. Munzinger,
A. Schneeweiss,
C. Sohn,
T. Strowitzki
et al.
|
S24
|
|
|
|
State version of autonomic regulation (aR): A new scale to distinguish between autonomic constitution and loss of regulation with regards to chemo- and mistletoe sensitivity
Introduction: Current inventories on quality of life in oncology such as the EORTC QLQ C30 mainly record the effects of chemo- or radiotherapy alongside functional scales and role scales. In this pape...
|
M. Kröz,
R. Zerm,
F. Schad,
M. Reif,
H.B. v. Laue,
Th. Storch,
G. Feder,
B. Brinkhaus,
S.N. Willich,
M. Girke
et al.
|
S25
|
|
|
|
Treatment of basal cell carcinoma with Viscum album lipophilic extract – A case series study
Purpose: Mistletoe (Viscum album L.) contains triterpenes (e.g. oleanolic acid, betulinic acid and lupeol) with apoptosis inducing, immunomodulating, antiulcer and wound healing activity. Viscum album...
|
C. Kunz,
H.R. Heiligtag,
A. Hintze,
K. Urech
|
S25
|
|
|
|
Diurnal cortisol profile in breast cancer patients before and during treatment with Viscum album (Iscador® P) for 3 or 6 months
Purpose: This randomized controlled feasibility trial examines the association between cortisol and quality of life in breast cancer patients during adjuvant or palliative treatment with Viscum album ...
|
A. Staudt,
A. Glenz,
B. Reinhard-Hennch,
A. Loewe-Mesch,
S. Lewicka,
H. Stammer,
J.J. Kuehn,
U. Abel,
J. Munzinger,
A. Schneeweiss,
C. Sohn,
T. Strowitzki,
C.v. Hagens
et al.
|
S25-S26
|
|
|
|
Mistletoe therapy for advanced pancreatic cancer. A group-sequential, randomised, open label study phase III ISRCTN 70760582
Primary hypothesis: Patients receiving Iscador Qu Spezial (IQuS) will show a higher overall survival rate.
|
Wilfried Tröger
|
S26
|
|
|
|
Author Index
|
|
S27-S28
|
|
